Q-omics provides the consensus-scored RNF185 profile across patient tissues and cancer cell-line models. RNF185 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RNF185 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, RNF185 protein abundance shows 19,574 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight KIRC, COAD, and BRCA as cancer lineages where RNF185 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNF185 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNF185 survival associations across molecular data types. RNF185 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNF185 RNA expression–survival associations across cancer types. High RNF185 expression shows unfavorable associations in UVM and ACC, but favorable associations in KIRC, BRCA, LGG and ESCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RNF185 RNA expression.
This table summarizes RNF185 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in LUAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for RNF185. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNF185 shows lower tumor expression in COAD, LUAD, THCA, READ and UCEC and higher tumor expression in HNSC. The COAD box plot shows higher RNF185 RNA expression in normal versus tumor tissue (log2 FC = −0.693, t-test p < 0.001).
This table shows molecular features associated with RNF185 in patient tissues and cancer cell lines. In patient samples, RNF185 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, RNF185 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
